Knowledge Hub

Chimeric Antigen Receptor (CAR) T cell Immunotherapy Pipeline on the Basis of Target, MOA, Route of Administration, Technology Involved and Molecule Type

Press Release   •   Feb 23, 2017 05:00 EST

DelveInsights, Chimeric Antigen Receptor (CAR) T cell Immunotherapy- Competitive Landscape, Pipeline and Market Analysis, 2017, report provides comprehensive insights about marketed and pipeline drugs across this Mechanism of action. Key objective of the report is to establish the understanding for all the marketed and pipeline drugs that fall under Chimeric Antigen Receptor (CAR) T cell Immunotherapy. This report provides information on the therapeutic development based on Chimeric Antigen Receptor (CAR) T cell Immunotherapy mechanism of action dealing with around 20+ active pipeline drugs. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. Report contains the development and sale activities for marketed drugs. DelveInsights Report also assesses the Chimeric Antigen Receptor (CAR) T cell Immunotherapy therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration. The report also covers the information for 20+ active companies involved in the therapeutic development of the products.

View Report @


  • The report provides competitive pipeline landscape of Chimeric Antigen Receptor (CAR) T cell Immunotherapy
  • The report provides the marketed drugs information including its sales, development activities and details of patent expiry
  • The report provides the insight of current and future market for Chimeric Antigen Receptor (CAR) T cell Immunotherapy
  • The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
  • Coverage of the Chimeric Antigen Receptor (CAR) T cell Immunotherapy pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
  • The report reviews key players involved in the therapeutics development for Chimeric Antigen Receptor (CAR) T cell Immunotherapy and also provide company profiling
  • The report also gives the information of dormant pipeline projects
  • Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
  • Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

Get Sample Copy of This Report @

Reasons to Buy

  • Identify emerging players with potentially strong product information and create effective counter-strategies to gain competitive advantage
  • Complete MOA intelligence and complete understanding over therapeutics development for Chimeric Antigen Receptor (CAR) T cell Immunotherapy
  • Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine.
  • Devise corrective measures for pipeline projects by understanding Chimeric Antigen Receptor (CAR) T cell Immunotherapy pipeline depth and focus of Indication therapeutics
  • Developing strategic initiatives to support your drug development activities.
  • Optimize your portfolio and keep you in touch with the rapidly changing pharmaceutical markets, and make the best decisions for your business.
  • Develop and design in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
  • Gaining a Full Picture of the Competitive Landscape for Evidence based Decisions

Table of Content :

Report Introduction

Executive Summary Snapshot

Executive Summary


Chimeric antigen receptor (CAR) T-cells


CARs and Generations

Advantages of CAR-T cells

Adverse Events with CAR T-cell Therapy

Limitations of Existing Technologies for CAR T-Cells

CAR-T Cell Therapy-Analysis

CAR-T Collaboration Deals

CAR-T Cells Therapy Collaborations and Deal Year

Collaborations & Deal Value Trends

Companies collaborations for future developments

CAR-T Acquisitions Deals

CAR-T Cells Therapy Acquisitions Trends

CAR-T Cells Therapy Acquisitions Offerings by Big Giants

New facilityfor the development of CAR-T cells

JCAR015: Major Set Back for Juno Therapeutics

CAR-T Licensing Opportunities

Pipeline Scenario

Pipeline Products under Development-An Overview

Pipeline Products under Development by Company

CAR T-cells Therapeutic Areas & Companies

CAR-T cells Targeted Antigens

CAR-T Therapies-Clinical trials & Completion Year

CAR T-cell Technologies & Companies Involved

CAR-T Safety Switches & Company involved

Companies with Upcoming CAR-T Therapeutics

Pipeline Profiles

Other Active Companies

Miltenyi Biotec

ZMKS International Cancer Therapies Biotechnologies Co. Ltd.

Upcoming Technologies Better than CARs

Market Drivers is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.